Cargando…

Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors

BACKGROUND: Immune-checkpoint inhibitors (ICIs) have revolutionized the treatment of hepatocellular carcinoma (HCC). However, long-term survival outcomes and treatment response of HCC patients undergoing immunotherapy is unpredictable. The study aimed to evaluate the role of alpha-fetoprotein (AFP)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Hong-Fei, Feng, Jin-Kai, Xiang, Yan-Jun, Wang, Kang, Zhou, Li-Ping, Liu, Zong-Han, Cheng, Yu-Qiang, Shi, Jie, Guo, Wei-Xing, Cheng, Shu-Qun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10268526/ https://www.ncbi.nlm.nih.gov/pubmed/37322411 http://dx.doi.org/10.1186/s12885-023-11003-0

Ejemplares similares

Diagnostic value of alpha-fetoprotein combined with neutrophil-to-lymphocyte ratio for hepatocellular carcinoma
por: Hu, Jian, et al.
Publicado: (2018)

Alpha-Fetoprotein Ratio Predicts Alpha-Fetoprotein Positive Hepatocellular Cancer Patient Prognosis after Hepatectomy
por: Sun, Li-Yue, et al.
Publicado: (2022)

Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha‐fetoprotein levels
por: Hsu, Po‐Yao, et al.
Publicado: (2021)

Preoperative alpha fetoprotein, total bilirubin, fibrinogen, albumin, and lymphocytes predict postoperative survival in hepatocellular carcinoma
por: Xu, Jia, et al.
Publicado: (2023)

Normal Alpha-Fetoprotein Hepatocellular Carcinoma: Are They Really Normal?
por: Lee, Chao-Wei, et al.
Publicado: (2019)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab
por: Wu, Yue Linda, et al.
Publicado: (2022)

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2021)

Neutrophil to lymphocyte ratio predicts prognosis in unresectable pancreatic cancer
por: Iwai, Naoto, et al.
Publicado: (2020)

The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation
por: Jiang, Tao, et al.
Publicado: (2021)

Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity
por: Wang, Xiaoping, et al.
Publicado: (2018)

Alpha-fetoprotein to transaminase ratio is related to higher diagnostic efficacy for hepatocellular carcinoma
por: Liu, Xu, et al.
Publicado: (2019)

The Landscape Of Alpha Fetoprotein In Hepatocellular Carcinoma: Where Are We?
por: Hu, Xin, et al.
Publicado: (2022)

Clinical Significance of Alpha-Fetoprotein in Alpha-Fetoprotein Negative Hepatocellular Carcinoma Underwent Curative Resection
por: Lin, Kongying, et al.
Publicado: (2021)

The Neutrophil-to-Lymphocyte Ratio (NLR) Predicts the Prognosis of Unresectable Intermediate and Advanced Hepatocellular Carcinoma Treated with Apatinib
por: Wang, Huaqi, et al.
Publicado: (2021)

Corrigendum: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Predictors of Outcomes in Patients With Unresectable Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2021)

Inflammatory cytokines and alpha-fetoprotein concentrations for predicting survival in patients with hepatocellular carcinoma
por: Han, Xue, et al.
Publicado: (2019)

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma
por: Lee, Pei-Chang, et al.
Publicado: (2020)

Efficacy and safety of transarterial chemoembolization plus antiangiogenic- targeted therapy and immune checkpoint inhibitors for unresectable hepatocellular carcinoma with portal vein tumor thrombus in the real world
por: Feng, Jin-Kai, et al.
Publicado: (2022)

Racial disparities in alpha‐fetoprotein testing and alpha‐fetoprotein status associated with the diagnosis and outcome of hepatocellular carcinoma patients
por: Wu, Guoyi, et al.
Publicado: (2019)

Serum alpha-fetoprotein as a predictive biomarker for tissue alpha-fetoprotein status and prognosis in patients with hepatocellular carcinoma
por: Wei, Zhewen, et al.
Publicado: (2022)

Cellular and genetic restrictions in the immunoregulatory activity of alpha-fetoprotein. II. Alpha-fetoprotein-induced suppression of cytotoxic T lymphocyte development
Publicado: (1978)

Association of Neutrophil, Platelet, and Lymphocyte Ratios with the Prognosis in Unresectable and Metastatic Pancreatic Cancer
por: Allen, Jessica, et al.
Publicado: (2020)

Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma
por: Hanif, Hira, et al.
Publicado: (2022)

Role of the pretreatment neutrophil-to-lymphocyte ratio in the survival of primary parotid cancer patients
por: Cheng, Guangyan, et al.
Publicado: (2019)

Clinical relevance of alpha-fetoprotein in determining resection margin for hepatocellular carcinoma
por: Lee, Jin-Chiao, et al.
Publicado: (2019)

Pretreatment Neutrophil–Lymphocyte Ratio: An Independent Predictor of Survival in Patients With Hepatocellular Carcinoma
por: Gao, Fangyuan, et al.
Publicado: (2015)

Neutrophil-to-lymphocyte ratio predicts overall survival of patients with combined hepatocellular cholangiocarcinoma
por: He, Chaobin, et al.
Publicado: (2018)

Pre- to postoperative alpha-fetoprotein ratio-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma
por: Yang, Chengkai, et al.
Publicado: (2023)

Neutrophil-lymphocyte Ratio Plus Prognostic Nutritional Index Predicts the Outcomes of Patients with Unresectable Hepatocellular Carcinoma After Transarterial Chemoembolization
por: Liu, Chang, et al.
Publicado: (2017)

Changes in neutrophil/lymphocyte and platelet/lymphocyte ratios after chemotherapy correlate with chemotherapy response and prediction of prognosis in patients with unresectable gastric cancer
por: WANG, FEN, et al.
Publicado: (2015)

Characterizations of Anti-Alpha-Fetoprotein-Conjugated Magnetic Nanoparticles Associated with Alpha-Fetoprotein for Biomedical Applications
por: Liao, Shu-Hsien, et al.
Publicado: (2017)

The Emerging Influences of Alpha-Fetoprotein in the Tumorigenesis and Progression of Hepatocellular Carcinoma
por: Xu, Ye, et al.
Publicado: (2021)

Neutrophil/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer
por: Gao, Yuan, et al.
Publicado: (2017)

Alpha-fetoprotein-L3 and Golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma
por: Zhang, Zhiguo, et al.
Publicado: (2015)

Quantitative proteomic profiling of hepatocellular carcinoma at different serum alpha-fetoprotein level
por: Wei, Xuyong, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma
por: Abd El Aziz, Mohamed A., et al.
Publicado: (2020)

Dynamic Changes in Neutrophil-to-Lymphocyte Ratio are Associated with Survival and Liver Toxicity Following Stereotactic Body Radiotherapy for Hepatocellular Carcinoma
por: Hsiang, Chih-Weim, et al.
Publicado: (2021)

Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib
por: Lué, Alberto, et al.
Publicado: (2017)

miR-630 Overexpression in Hepatocellular Carcinoma Tissues is Positively Correlated with alpha-Fetoprotein
por: Zhang, Jian-wen, et al.
Publicado: (2015)

Alpha-1-acid glycoprotein as potential biomarker for alpha-fetoprotein-low hepatocellular carcinoma
por: Bachtiar, Indra, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_2k13d4ukiv00kfr39bomupm00o